Marko Simunovic1, Daniela Supe-Domic2, Zeljka Karin3, Marina Degoricija4, Martina Paradzik5, Josko Bozic6, Ivana Unic1, Veselin Skrabic1. 1. Department of Pediatrics, University Hospital of Split, Split, Croatia. 2. Department of Medical Laboratory Diagnostics, University Hospital of Split, Split, Croatia. 3. Public Health Institute of Split and Dalmatia County, Split, Croatia. 4. Department of Medical Chemistry and Biochemistry, University of Split School of Medicine, Split, Croatia. 5. Department of Ophthalmology, University Hospital of Split, Split, Croatia. 6. Department of Pathophysiology, University of Split School of Medicine, Split, Croatia.
Abstract
BACKGROUND: Catestatin is a chromogranin A-derived peptide with a wide spectrum of biological activities, such as inhibiting catecholamine release, decreasing blood pressure, stimulating histamine release, reducing beta-adrenergic stimulation, and regulating oxidative stress. OBJECTIVES: The aims of our study were to determine serum catestatin concentrations in obese children and adolescents in regard to presence or absence of metabolic syndrome (MS) and to evaluate the possible relations between catestatin levels and other cardiovascular risk factors. SUBJECTS: Ninety-two obese subjects with a body mass index z score > 2, aged 10 to 18 years, and 39 healthy, normal weight controls were enrolled in the study. METHODS: Serum catestatin concentrations were measured using an enzyme-linked immunosorbent assay. RESULTS: Significantly lower serum catestatin concentrations were recorded in the group of obese subjects compared with a control group (10.03 ± 5.05 vs 13.13 ± 6.25 ng/mL, P = 0.004). Further analyses revealed significantly lower catestatin concentrations in the subgroup of obese patients with MS (9.02 ± 4.3 vs 10.54 ± 5.36 vs 13.13 ± 6.25, P = 0.008). Serum catestatin concentrations were significantly negatively correlated with diastolic blood pressure (r = -0.253, P = 0.014), homeostatic model assessment of insulin resistance (r = -0.215, P = 0.037) and high sensitivity C-reactive protein (r = -0.208, P = 0.044). CONCLUSIONS: To the best of our knowledge, this study is the first to report catestatin concentrations in obese children and adolescents and their possible relations with MS and cardiovascular risk factors in a pediatric population. Obese subjects with MS have lower serum catestatin concentrations than obese subjects without MS and controls.
BACKGROUND:Catestatin is a chromogranin A-derived peptide with a wide spectrum of biological activities, such as inhibiting catecholamine release, decreasing blood pressure, stimulating histamine release, reducing beta-adrenergic stimulation, and regulating oxidative stress. OBJECTIVES: The aims of our study were to determine serum catestatin concentrations in obesechildren and adolescents in regard to presence or absence of metabolic syndrome (MS) and to evaluate the possible relations between catestatin levels and other cardiovascular risk factors. SUBJECTS: Ninety-two obese subjects with a body mass index z score > 2, aged 10 to 18 years, and 39 healthy, normal weight controls were enrolled in the study. METHODS: Serum catestatin concentrations were measured using an enzyme-linked immunosorbent assay. RESULTS: Significantly lower serum catestatin concentrations were recorded in the group of obese subjects compared with a control group (10.03 ± 5.05 vs 13.13 ± 6.25 ng/mL, P = 0.004). Further analyses revealed significantly lower catestatin concentrations in the subgroup of obesepatients with MS (9.02 ± 4.3 vs 10.54 ± 5.36 vs 13.13 ± 6.25, P = 0.008). Serum catestatin concentrations were significantly negatively correlated with diastolic blood pressure (r = -0.253, P = 0.014), homeostatic model assessment of insulin resistance (r = -0.215, P = 0.037) and high sensitivity C-reactive protein (r = -0.208, P = 0.044). CONCLUSIONS: To the best of our knowledge, this study is the first to report catestatin concentrations in obesechildren and adolescents and their possible relations with MS and cardiovascular risk factors in a pediatric population. Obese subjects with MS have lower serum catestatin concentrations than obese subjects without MS and controls.
Authors: Toni Kljakovic-Gaspic; Daria Tokic; Dinko Martinovic; Marko Kumric; Daniela Supe-Domic; Sanda Stojanovic Stipic; Nikola Delic; Josip Vrdoljak; Marino Vilovic; Tina Ticinovic Kurir; Josko Bozic Journal: J Clin Med Date: 2022-08-02 Impact factor: 4.964
Authors: Francis Schneider; Pierrick Le Borgne; Jean-Etienne Herbrecht; François Danion; Morgane Solis; Sophie Hellé; Cosette Betscha; Raphaël Clere-Jehl; François Lefebvre; Vincent Castelain; Yannick Goumon; Marie-Hélène Metz-Boutigue Journal: Front Immunol Date: 2022-09-29 Impact factor: 8.786